Attention Deficit Hyperactivity Disorder (ADHD) is a chronic neurodevelopmental disorder with impairments such as attention difficulty, hyperactivity, and impulsiveness.1On August 1, 2023, the FDA released a statement addressing the continued prescription stimulant shortage acknowledging the important role that these medications play in the treatment of ADHD. The nationwide stimulant shortage, resulting in time-consuming and frustrating searches for psychostimulant medications among providers and patients, exposes a need to explore viable alternatives for ADHD symptom management. Dextroamphetamine, the first and only FDA-approved transdermal amphetamine patch for the treatment of ADHD in patients ≥6 years old, may assist in mitigating the current nationwide stimulant shortage.4